Advanced search
Publication Cover
Blood Pressure Volume 24, 2015 - Issue 1
Submit an article Journal homepage
509
Views
24
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Physician (investigator) inertia in apparent treatment-resistant hypertension – Insights from large randomized clinical trials. Lennart Hansson Memorial Lecture

Sverre E. KjeldsenUniversity of Oslo, Ullevaal Hospital, Oslo, Norway;University of Michigan Health System, Ann Arbor, Michigan, USACorrespondence[email protected]
,
Stevo JuliusUniversity of Michigan Health System, Ann Arbor, Michigan, USA
,
Björn DahlöfSahlgrenska University Hospital, Gothenburg, Sweden
&
Michael A. WeberSUNY Downstate Medical College, Brooklyn, New York, USA
Pages 1-6 | Received 07 Jun 2014, Accepted 07 Jul 2014, Published online: 27 Aug 2014

Figures & data

Figure 1. Change in mean systolic blood pressure (SBP) during the first year of blinded treatment in the LIFE study (n = 9192). Error bars represent standard error of the mean. LIFE, Losartan Intervention For Endpoint reduction.
Figure 1. Change in mean systolic blood pressure (SBP) during the first year of blinded treatment in the LIFE study (n = 9192). Error bars represent standard error of the mean. LIFE, Losartan Intervention For Endpoint reduction.
Figure 2. Number of patients per country with systolic blood pressure > 140 mmHg and remaining on the initial dose (50 mg) of test drug (not uptitrated by investigator) from September 2000 to April 2001 in the LIFE study. LIFE, Losartan Intervention For Endpoint reduction.
Figure 2. Number of patients per country with systolic blood pressure > 140 mmHg and remaining on the initial dose (50 mg) of test drug (not uptitrated by investigator) from September 2000 to April 2001 in the LIFE study. LIFE, Losartan Intervention For Endpoint reduction.

Table I. Number of patients per country with systolic blood pressure > 140 mmHg and remaining on the initial dose (50 mg) of test drug (not uptitrated by investigator) from September 2000 to April 2001 in the LIFE study.

Figure 3. Mean systolic blood pressure (SBP) during the first 30 months of the VALUE trial in patients with untreated or treated hypertension at baseline. Error bars represent standard deviation. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.
Figure 3. Mean systolic blood pressure (SBP) during the first 30 months of the VALUE trial in patients with untreated or treated hypertension at baseline. Error bars represent standard deviation. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.
Figure 4. Percentage of patients reaching systolic and diastolic blood pressure (SBP and DBP) targets during the first 30 months of the VALUE trial, and percentages of patients receiving the lowest and highest doses of study drug after 6 and 30 months. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.
Figure 4. Percentage of patients reaching systolic and diastolic blood pressure (SBP and DBP) targets during the first 30 months of the VALUE trial, and percentages of patients receiving the lowest and highest doses of study drug after 6 and 30 months. VALUE, Valsartan Antihypertensive Long-term Use Evaluation.
Figure 5. Proportion of patients not reaching target diastolic blood pressure (DBP), according to dose titration step, in 4 years of the ASCOT study. ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial.
Figure 5. Proportion of patients not reaching target diastolic blood pressure (DBP), according to dose titration step, in 4 years of the ASCOT study. ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial.
Figure 6. Number of randomized patients and blood pressure control rate (< 140/90 mmHg) over time in the ACCOMPLISH trial (data as of October 2006). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.
Figure 6. Number of randomized patients and blood pressure control rate (< 140/90 mmHg) over time in the ACCOMPLISH trial (data as of October 2006). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.
Figure 7. Proportions of patients at each dose level (DL) according to blood pressure (BP) control defined as BP < 140/90 mmHg or BP < 130/80 mmHg at month 6 in the ACCOMPLISH trial (data as of October 2005). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.
Figure 7. Proportions of patients at each dose level (DL) according to blood pressure (BP) control defined as BP < 140/90 mmHg or BP < 130/80 mmHg at month 6 in the ACCOMPLISH trial (data as of October 2005). ACCOMPLISH, Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension.

Table II. Blood pressure control (< 140/90 mmHg) for all randomized patients in the ACCOMPLISH trial (as of October 2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.